Results from a Phase 3 trial in Moderate to Moderately Severe Community Acquired Bacterial Pneumonia (CABP) Treated As Outpatients With a New Oral Macrolide, Solithromycin

1. Cempra, Inc., Chapel Hill, NC, United States; 2. InClin, San Francisco, CA, United States; 3. Instiuto Medico Platense, La Plata, Argentina; 4. Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases, Ruse, Bulgaria; 5. A & L Clinical Research, Miami, FL, United States; 6. Mercury Clinical Research, Houston, TX, United States; 7. Worthwhile Clnical Trials, Gauteng, South Africa; 8. Sf. Pantelimon Emergency Clinical Hospital, Bucharest, Romania; 9. FOMAT Luis Vernaza Hospital, Guayaquil, Ecuador; 10. Medsantrud City Clinical Hospital #23, Moscow, Russian Federation; 11. Park Medical Centre, Witbank, South Africa; 12. University of Alberta, Edmonton, AB, Canada; 13. JM Research, Houston, TX, United States; 14. Andrzej Dyczek Good Doctor Specialist Outpatient Clinics, Cracow, Poland; 15. Centro Medico Dra. De Salvo, Ciudad de Buenos Aires, Argentina; 16. Dr. Victor Babes Clinical Hospital for Infectious Diseases and Pneumophysiology, Craiova, Romania.